Patents by Inventor Alexander James Bridges

Alexander James Bridges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucosylceramide synthase inhibitors for the treatment of diseases
    Patent number: 10927092
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 23, 2021
    Inventors: Bing Wang, Daniel Chu, Alexander James Bridges
  • SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE
    Publication number: 20200131176
    Abstract: The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.
    Type: Application
    Filed: July 5, 2018
    Publication date: April 30, 2020
    Inventors: Yuntao SONG, Alexander James BRIDGES, Xiaoqi CHEN
  • Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
    Patent number: 10435388
    Abstract: The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 8, 2019
    Assignee: CS Pharmatech Limited
    Inventors: Yuntao Song, Alexander James Bridges
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES
    Publication number: 20190263775
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Application
    Filed: January 31, 2019
    Publication date: August 29, 2019
    Inventors: Bing Wang, Daniel Chu, Alexander James Bridges
  • Glucosylceramide synthase inhibitors for the treatment of diseases
    Patent number: 10227323
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: March 12, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Bing Wang, Daniel Chu, Alexander James Bridges
  • SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE
    Publication number: 20190023689
    Abstract: The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Inventors: Yuntao SONG, Alexander James BRIDGES
  • Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (G) quinazoline trisodium salt
    Patent number: 9458188
    Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: October 4, 2016
    Assignee: BTG INTERNATIONAL LIMITED
    Inventors: James Alan Kerschen, Alexander James Bridges, Milind D. Choubal, Sean Mark Dalziel, Thomas Elliott Jacks, Andrew S. Thompson, James Robert Zeller
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES
    Publication number: 20160229830
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Application
    Filed: September 19, 2014
    Publication date: August 11, 2016
    Inventors: Bing Wang, Daniel Chu, Alexander James Bridges
  • MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
    Publication number: 20160214996
    Abstract: The compounds and salts of the present invention inhibit kinases, especially the anaplastic lymphoma kinase (ALK) and the HGF receptor tyrosine kinase (RTK) c-Met, and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
    Type: Application
    Filed: April 1, 2016
    Publication date: July 28, 2016
    Inventors: Yuntao Song, Alexander James Bridges
  • Synthesis of cyclopentaquinazolines
    Patent number: 8809526
    Abstract: A method of producing 6-amino-cyclopenta[g]quinazolines, in enantiomerically enriched form, is provided. In particular, the method may be applicable to the synthesis of N—{N-{4-[N-((6S)-2 -hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclo-penta[g]quinazolin-6-yl)-N-(prop-2 -ynyl)amino]benzoyl}-L-?-glutamyl}-D-glutamic acid (ONX-0801).
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: August 19, 2014
    Assignee: ONYX Pharmaceuticals, Inc.
    Inventors: James Alan Kerschen, Alexander James Bridges, Sean Mark Dalziel, Olivier Dapremont, Hyunjung Kim, Andrew S. Thompson, James Robert Zeller
  • EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT
    Publication number: 20130345423
    Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 26, 2013
    Applicant: Onyx Pharmaceutical, Inc.
    Inventors: James Alan Kershen, Thomas Elliott Jacks, Andrew S. Thompson, Alexander James Bridges, Milind D. Choubal, Sean Mark Dalziel, James Robert Zeller
  • Synthesis of Cyclopentaquinazolines
    Publication number: 20130211082
    Abstract: A method of producing 6-amino-cyclopenta[g]quinazolines, in enantiomerically enriched form, is provided. In particular, the method may be applicable to the synthesis of N-{N-{4-[N-((6S)-2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclo-penta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-?-glutamyl}-D-glutamic acid (ONX-0801).
    Type: Application
    Filed: July 15, 2011
    Publication date: August 15, 2013
    Applicant: ONYX Pharmaceuticals, Inc.
    Inventors: James Alan Kerschen, Alexander James Bridges, Sean Mark Daizlel, Olivier Dapremont, Hyunjung Kim, Andrew S. Thompson, James Robert Zeller
  • Pyrimido[5,4-d]pyrimidines derivatives as irreversible inhibitors of tyrosine kinases
    Patent number: 7786131
    Abstract: The present invention relates to pyrimido [5,4-d] pyrimidine compounds of Formula II or a pharmaceutically acceptable salt thereof, wherein Q is and X, E1, E2, E3, R6 and p are as defined herein. The compounds of this invention are irreversible inhibitors of tyrosine kinases and are useful in the treatment of cancer, atherosclerosis, restenosis, endometriosis and psoriasis.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: August 31, 2010
    Assignee: Warner-Lambert Company
    Inventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
  • Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
    Publication number: 20080171728
    Abstract: Disclosed herein are methods for preparing steroids and Vitamin D derivatives having the unnatural beta (usually S) configuration at C20, the methods comprising the use of compounds of the formula: wherein R is as defined herein. Also disclosed are steroids and Vitamin D derivatives made using the methods disclosed herein and pharmaceutical compositions comprising said steroids and Vitamin D derivatives.
    Type: Application
    Filed: January 11, 2008
    Publication date: July 17, 2008
    Inventor: Alexander James Bridges
  • 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
    Patent number: 7169816
    Abstract: Phenylamino benzhydroxamic acid derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: January 30, 2007
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Haile Tecle
  • Method for treating chronic pain using MEK inhibitors
    Patent number: 7030119
    Abstract: The invention features a method for treating chronic pain using a compound of formula (I).
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: April 18, 2006
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Haile Tecle, Alistair Dixon, Kevin Lee, Robert Pinnock
  • 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
    Patent number: 7019033
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: March 28, 2006
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
    Patent number: 6821963
    Abstract: Phenylamino benzhydroxamic acid derivatives of formula (I) where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: November 23, 2004
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Haile Tecle
  • Preparation of substituted quinazolines
    Publication number: 20040158065
    Abstract: Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula 1 are disclosed. Such inhibitors, which include N-[4-(3-chloro-4-floro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, are useful for treating cancer, restenosis, atherosclerosis, endometriosis and psoriasis. The disclosed methods employ protecting schemes to minimize undesirable diacryloylamino-quinazoline side products.
    Type: Application
    Filed: February 4, 2004
    Publication date: August 12, 2004
    Inventors: Hubert Barth, Alexander James Bridges, Ronald J. Heemstra, Nicole Marcia Horne, Robert Craig Hughes, Thomas Elliott Jacks, Dennis Joseph McNamara, Simon Schneider, Klaus Steiner, Peter Laurence Toogood, Roy Thomas Winters
  • Treatment of asthma with MEK inhibitors
    Publication number: 20040141924
    Abstract: This invention provides a method of preventing or treating asthma by administering to a patient in need of treatment an effective amount of a selective MEK inhibitor, especially a phenyl amine of Formula I and II: 1
    Type: Application
    Filed: January 7, 2004
    Publication date: July 22, 2004
    Inventors: Alexander James Bridges, David Thomas Dudley, James Leslie Mobley, Alan Robert Saltiel